Background: Common variants in the gene GATA binding protein 4 (GATA4) show association with alcohol dependence (AD). The aim of this study was to identify rare variants in GATA4 in order to elucidate the role of this gene in AD susceptibility. Identification of rare variants may provide a more complete picture of the allelic architecture at this risk locus.
A LCOHOL DEPENDENCE (AD) has a multifactorial etiology and an estimated heritability of 40 to 60% (Agrawal and Lynskey, 2008; Enoch and Goldman, 2001; Rietschel and Treutlein, 2013) . Candidate-, linkage-, and genome-wide association studies (GWAS) of AD have identified multiple candidate genes (Samochowiec et al., 2014) . At the time of writing, the best replicated risk factors in the European population are genetic variants in the alcohol dehydrogenase (ADH) gene cluster. Identification of these variants was initiated more than 15 years ago, when largescale linkage studies implicated a risk locus on chromosome 4q (Long et al., 1998; Prescott et al., 2006; Reich et al., 1998; Samochowiec et al., 2014) . Subsequent GWAS then pinpointed the association signal to the ADH gene cluster on chromosome 4q23. The importance of this gene cluster has since been confirmed in several independent GWAS (Frank et al., 2012; Gelernter et al., 2014; Park et al., 2013; Treutlein et al., 2009) . Besides providing further genetic evidence for genes already implicated in AD pathogenesis, GWAS facilitate the unraveling of novel genetic risk factors.
One gene of interest is GATA binding protein 4 (GATA4) on chromosome 8p23.1, which was first identified in the GWAS of AD by Treutlein and colleagues (2009) . The discovery step of this GWAS included 487 AD patients and 1,358 controls, and the subsequent follow-up study investigated the 139 most promising single nucleotide polymorphisms (SNPs) in 1,024 AD patients and 996 controls. The intronically located GATA4 variant rs13273672 was among the 15 variants with at least nominal significance in the replication cohort.
Subsequent studies have provided further evidence that GATA4 is a promising candidate gene for AD. First, the association reported by Treutlein and colleagues (2009) was replicated in an independent GWAS performed by Edenberg and colleagues (2010) . In a subcohort comprising patients with early onset AD (≤22 years), the SNP rs13273672 achieved a p-value of 1.6 9 10 À03 (Edenberg et al., 2010) . Second, Karpyak and colleagues (2014) genotyped 816 AD patients and 1,248 controls for a total of 11 SNPs located within GATA4. Five of the 11 tested SNPs in GATA4 showed a nominally significant association with AD, although no result withstood correction for multiple testing. Furthermore, a global test performed using a principle component analysis revealed a significant association at the gene level (p = 0.009; Karpyak et al., 2014) . Third, in the PRE-DICT study, Kiefer and colleagues (2011) found that the GATA4 variant rs13273672 showed a nominally significant association with relapse to heavy drinking within 12 weeks of treatment. This randomized, double-blind, placebo-controlled multicenter trial included 374 AD patients (Kiefer et al., 2011) . Fourth, Jorde and colleagues (2014) genotyped rs13273672 in 81 AD patients, and identified GATA4 genotype-dependent differences in alcohol cue-induced amygdala activity.
The search for rare variants in GATA4 may provide a more complete picture of the allelic architecture at this risk locus and identify variants with higher penetrance. The latter might be better suited for functional follow-up studies than common variants with lower penetrance. The aim of this study was to elucidate the role of GATA4 in AD susceptibility by identifying rare variants. All protein-coding exons of GATA4 were sequenced in 528 AD patients and 517 controls of German descent. Variants that were both exclusive to patients and predicted by in silico tools to be functionally relevant were then genotyped in an independent cohort of 655 patients and 1,501 controls.
MATERIALS AND METHODS
The study was approved by the respective ethics committees, and all participants provided written informed consent prior to inclusion. All study procedures were performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). All participants were of German descent according to self-reported ancestry.
Sample Description-Sanger Sequencing and Replication Cohort
The majority of study participants were genome-wide genotyped as part of previously published studies (see Frank et al., 2012; Treutlein et al., 2009) . For these individuals, principal component analysis or multidimensional scaling was performed, respectively. No population substructure was identified.
Patient Sample
The Sanger sequencing cohort comprised 528 AD patients. The replication study cohort comprised 655 independent AD patients. Patients were recruited through consecutive admissions to psychiatry and addiction medicine departments of several German psychiatric hospitals as described elsewhere (see Frank et al., 2012; Treutlein et al., 2009) . All patients fulfilled the DSM-IV criteria (American Psychiatric Association, 1994) for AD and had a history of hospitalization for the treatment or prevention of severe withdrawal symptoms. A more detailed phenotypic description of the sample is provided in Table 1a and 1b.
Control Sample
The Sanger sequencing cohort comprised 517 controls. The replication step cohort comprised 1,501 independent controls. The population-based control samples were recruited from volunteer blood donors in collaboration with the Baden-W€ urttemberg State Association of the German Red Cross. A more detailed phenotypic description of the sample is provided in Table 1a and 1b.
Sanger Sequencing
Primer design was based on the NCBI37/hg19 reference sequence of the longest GATA4 protein-coding isoform (ENST00000335135). The GATA4 gene comprises 7 exons. Six of these are coding exons. The 6 coding exons and their flanking sequences (+/À 10 bp of each exon) were amplified. Sanger sequencing was performed using the service offered by Beckman Coulter Genomics (Takeley, UK). The identified variants were confirmed at the Institute of Human Genetics in Bonn by sequencing the complementary strand of a second, independent amplicon. The obtained nucleotide sequences were analyzed using Seqman TM II (DNASTAR, Madison, WI). Primer sequences are obtainable upon request.
In Silico Analysis of Sequence Variants
To determine the effect of a DNA variant on the amino acid sequence and protein function, the following in silico prediction n.a., not available; N/A, not applicable; SD, standard deviation; AD, alcohol dependence; ADS, alcohol dependence scale. tools were used: (i) MutationTaster (Schwarz et al., 2010;  http://mutationtaster.org/; NCBI37/Ensembl 69); (ii) PolyPhen-2 version 2.2.2 (Adzhubei et al., 2013; http://genet(19) ics.bwh.har vard.edu/pph2/); (iii) SIFT (Ng and Henikoff, 2001 ; http://sift.jc vi.org/; Ensemble 66); (iv) and PROVEAN (Choi and Chan, 2015;  http://provean.jcvi.org/index.php; Ensemble 66).
Replication Analysis-Selection of Variants and Genotyping
Five variants were selected for genotyping using the following criteria: (i) the variant was not detected in the Sanger sequencing control cohort; and (ii) the variant was predicted to be functionally relevant by at least 1 prediction tool. The primer molecules for the multiplex reaction were designed using the Assay Design Suite tool (www.agenacx.com; Agena Bioscience, Inc., San Diego, CA). Assay designs were successful for all 5 variants. Primer sequences and assay conditions are available upon request.
Replication Analysis-Quality Control
Five variants (c.939G>T, c.627C>T, c.699G>A, c.1137C>T, and g.73282C>A) were genotyped using Agena Bioscience's Mass Array System and iPlex Gold reagents in accordance with the manufacturer's instructions. Genotyping was performed at the Department of Genomics, Life & Brain Center at the University of Bonn.
Only variants with a call rate of >90% were included in the subsequent analyses. Individuals with a DNA call rate of <90% were removed from the data set. The positive control for the variant g.73282C>A was not detected in all 384-well plates, and this variant was therefore excluded from the study. After quality control, data for 4 SNPs, as obtained from 651 patients and 1,497 controls, were available for analysis.
Statistical Analysis
Fisher's exact test (2 sided) was used to test for an association between the single variants and AD.
RESULTS

Sanger Sequencing
All 6 coding exons of GATA4 (i.e., exons 2 to 7) were sequenced. High-quality sequence data were available from: (i) 484 patients and 513 controls for exon 2; (ii) 513 patients and 511 controls for exon 3; (iii) 518 patients and 501 controls for exon 4; (iv) 515 patients and 511 controls for exon 5; (v) 515 patients and 500 controls for exon 6; and (vi) 507 patients and 513 controls for exon 7.
Overall, 19 different heterozygous variants were identified. One of these is a known common SNP (rs3729856). No association was detected between rs3729856 and AD. The remaining 18 variants are listed in Table 2 . These comprised: (i) 8 nonsynonymous variants; (ii) 7 synonymous variants; and (iii) 3 intronic variants (Table 2) . Of these, the following 7 were detected exclusively among our discovery patient cohort: (i) 3 nonsynonymous variants (E313D, A343T, and A346V); (ii) 3 synonymous variants (D209D, T233T, and S379S); and (iii) 1 intronic variant (g.73282C>A). A total of 18 different heterozygous rare variants were identified in the discovery step. All chromosomal positions are given according to NCBI37/hg19. N/A, not applicable; prob. dam., probably damaging; dis. caus., disease causing; functionally relevant, number of in silico tools that predict the variant to be at least probably disease causing.
Of the 7 patient-specific variants, the nonsynonymous variant E313D in exon 5 was predicted to be functionally relevant by SIFT, PROVEAN, and MutationTaster. The remaining 2 patient-specific, nonsynonymous variants were predicted to be benign by all prediction tools applied. All 3 patient-specific synonymous variants were predicted to be functionally relevant by MutationTaster. The PolyPhen-2, SIFT, and PROVEAN tools are unable to predict the potential functional relevance of synonymous or intronic variants. MutationTaster predicted the intronic variant g.73282C>A to be disease causing.
With the exception of the synonymous variant T233T (detected in 8/513 patients; 1.56%), all patient-specific variants were single observations. No patient or control carried more than 1 variant in GATA4.
The following 5 patient-specific and potentially functionally relevant variants were selected for follow-up in the independent replication cohort: (i) D209D and T233T in exon 3; (ii) E313D in exon 5; (iii) S379S in exon 6; and (iv) the intronic variant g.73282C>A.
Replication Analysis
Four of the 5 selected variants were genotyped successfully. The assay for g.73282C>A did not detect the positive control reliably, and this variant was therefore excluded from the downstream analysis. The results of the replication analysis are shown in Table 3 . Only the synonymous variant S379S (c.1137C>T) remained patient specific (1/1,166 patients vs. 0/1,997 controls in the combined sample; p > 0.05). No other patient from the replication cohort carried the S379S variant. In the replication cohort, 12 T233T (c.699G>A) carriers were detected among the patients (1.84%). In total, 17 T233T variant carriers were detected among the controls (1.14%). For D209D and E313D, no additional variant carriers were detected in the replication patient cohort. However, D209D and E313D variant carriers were identified in the replication control cohort. None of the 4 investigated variants showed a nominally significant association with AD in the replication cohort.
DISCUSSION
The present study detected no significant association between AD and rare variants in GATA4. The only variant found exclusively in patients was S379S (c.1137C>T) (1/1,166 patients vs. 0/1,997 controls in the combined sample). This mutation is not listed in ClinVar (http:// www.ncbi.nlm.nih.gov/clinvar/). Within the cohorts reported in the Exome Aggregation Consortium (ExAC), the variant c.1137C>T was identified in 1/33,075 non-Finnish European samples (Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) [(September, 2015 ) accessed]). Given the rarity of c.1137C>T, no definite conclusions can yet be drawn concerning its relevance to AD susceptibility. Replication analyses in independent study cohorts are warranted to elucidate its role in AD pathogenesis.
Notably, a marked difference in the frequency of the variant c.669G>A was observed between the Sanger sequencing control cohort (0/511) and the replication control cohort (17/ 1,497). Although this variant was associated with AD in the Sanger sequencing cohort, this association was not replicated. To test whether this frequency difference was attributable to the different genotyping methods, we first regenotyped the Sanger sequencing control cohort for c.669G>A using the Sequenom assay applied in the replication study and then Sanger-sequenced exon 3 in all c.669G>A variant carriers identified in the replication cohort. The re-genotyping of the Sanger sequencing control cohort confirmed the absence of c.669G>A variant carriers, and all variant carriers identified in the replication study were unambiguously detected using Sanger sequencing. The possibility that the frequency difference was due to the different genotyping methods can therefore be excluded. Within the cohorts reported in ExAC, the variant c.669G>A was identified in 263/33,364 non-Finnish European samples (including 2 homozygous variants). The possibility that (as yet unknown) confounding factors explain the absence of the variant c.669G>A in the Sanger sequencing cohort cannot be excluded. However, no pronounced phenotypic differences were present in the investigated inhouse control cohorts. The frequency differences observed between the present Sanger sequencing control cohort, the present replication-genotyping control cohort, and the cohorts of the ExAC demonstrate the importance of replication analyses.
The present study had several limitations. First, due to the limited sample size of our initial Sanger sequencing cohort and the genotyping of only selected variants in the replication cohort, it is likely that only a small fraction of the rare variants that contribute to the allelic spectrum of GATA4 were detected. Sequencing studies in larger AD cohorts are warranted to provide a more complete overview of rare sequencing variants in this gene. Second, none of the controls were screened for AD, which may have led to false-negative findings for some genuinely associated regions. Third, our analysis focused on exonic variants. Further studies are required to elucidate the contribution of noncoding variants to the allelic spectrum of GATA4 in patients with AD. Fourth, as the aim of the present study was to identify rare risk-associated variants, the study design selected against variants identified in the Sanger sequencing control cohort. As a consequence of this, the study design precluded the identification of potentially protective variants in GATA4. Fifth, we did not perform burden analysis in the Sanger sequencing cohort to find the excess of risk or protective variants in the AD patients as our study design did not allow for a replication of the results.
In conclusion, although patient-specific rare variants of GATA4 were identified in similarly sized patient versus control samples, none received support in an independent replication step. However, given previous robust association findings for common variants (12 to 16), GATA4 remains a promising candidate gene for AD, and thus warrants further investigation.
